[Impact of angiotensionogen and angiotensin II receptor type 1 gene polymorphisms on the development and course of

Related Experiment Video

Updated: May 12, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

A T Tepliakov, S N Shilov, E N Berezikova

    Terapevticheskii Arkhiv
    |March 29, 2013
    PubMed

    Insights

    Gene variants in angiotensinogen (AGT) and angiotensin II receptor type 1 (AGTR1) are linked to chronic heart failure (CHF) development and progression in coronary heart disease (CHD) patients.

    Area of Science:

    • Cardiovascular Genetics
    • Molecular Cardiology
    • Genetics of Heart Failure

    Background:

    • Coronary heart disease (CHD) is a major cause of chronic heart failure (CHF).
    • Genetic factors play a role in the pathogenesis and progression of CHF.
    • The renin-angiotensin-aldosterone system (RAAS) is implicated in cardiovascular disease, with angiotensinogen (AGT) and its receptor (AGTR1) as key components.

    Purpose of the Study:

    • To investigate the association between polymorphisms in the angiotensinogen (AGT) gene (M235T) and angiotensin II receptor type 1 (AGTR1) gene (A1166C) with the development and course of chronic heart failure (CHF) in patients with coronary heart disease (CHD).

    Main Methods:

    • A case-control study involving 226 CHF patients with CHD and 136 healthy controls.
    • Genotyping was performed using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis.
    • Analysis focused on M235T polymorphism of the AGT gene and A1166C polymorphism of the AGTR1 gene.

    Main Results:

    • The T allele of the AGT M235T polymorphism was associated with increased risk and unfavorable course of CHF in CHD patients.
    • The M allele of the AGT M235T polymorphism was linked to a favorable course of CHF.
    • The C allele and A/C genotype of the AGTR1 A1166C polymorphism were associated with CHF development, while the A allele and A/A genotype showed a protective effect.
    • No significant differences in genotype or allele frequencies of AGTR1 A1166C were observed based on CHF severity or course.

    Conclusions:

    • Polymorphisms in the AGT (M235T) and AGTR1 (A1166C) genes are associated with the development of chronic heart failure (CHF) in patients with coronary heart disease (CHD).
    • These genetic variations may serve as potential biomarkers for CHF risk and progression in this patient population.
    Abstract

    More Related Videos

    Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

    Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

    Published on: September 28, 2015

    Related Concept Videos

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...